<DOC>
	<DOCNO>NCT00302016</DOCNO>
	<brief_summary>This study evaluate AMN107 safe adult chronic myeloid leukemia resistant intolerant imatinib provide patient access new drug drug become commercially available .</brief_summary>
	<brief_title>Expanded Access Program AMN107 Imatinib-resistant Intolerant Adult Patients With Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion : Imatinibresistant intolerant Philadelphia chromosomepositive chronic myeloid leukemia blast crisis , accelerated phase , chronic phase . Chronic myeloid leukemia patient treat investigational tyrosine kinase inhibitor . Laboratory value within normal limit . Exclusion criterion : Impaired cardiac function . Acute chronic liver renal disease consider unrelated tumor . Other concurrent severe and/or uncontrolled medical condition ( e.g. , uncontrolled diabetes , active uncontrolled infection ) could cause unacceptable safety risk compromise compliance protocol . Patients currently receive treatment medication potential prolong QT interval inhibit metabolism AMN107 ( CYP3A4/5 inhibitor ) . Patients history another malignancy currently clinically significant currently require active intervention . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>AMN 107</keyword>
	<keyword>Imatinib resistant intolerant</keyword>
	<keyword>nilotinib</keyword>
	<keyword>enact</keyword>
</DOC>